Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03325075 · ClinicalTrials.gov registry record · Phase 1
Safety, Tolerability, and Immunogenicity of VAL-181388 in Healthy Participants
A Phase 1 study, sponsored by ModernaTX.
- Completed
- Registry status
- Phase 1
- Development phase
- 60
- Enrollment target
NCT03325075 is a Phase 1 study that has completed, run by ModernaTX. The registered enrollment target is 60 participants.
The verdict
NCT03325075, a Phase 1 study, has completed, sponsored by ModernaTX.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 60 participants
- Enrollment target
Study Summary
This clinical study will assess the safety, tolerability, and immunogenicity of VAL-181388 in healthy participants.
Interventions
- OTHER Placebo
- BIOLOGICAL VAL-181388
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2017-07-19 |
| Est. Completion | 2019-03-19 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03325075
The ClinicalTrials.gov registry entry for NCT03325075 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is ModernaTX, which has 90 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03325075 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03325075 about?
NCT03325075 is a clinical study titled "Safety, Tolerability, and Immunogenicity of VAL-181388 in Healthy Participants". This clinical study will assess the safety, tolerability, and immunogenicity of VAL-181388 in healthy participants.
What is the current status of trial NCT03325075?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 60 participants. The study started on 2017-07-19. Estimated completion is 2019-03-19.
What interventions are being tested in trial NCT03325075?
The interventions under investigation include: Placebo (OTHER), VAL-181388 (BIOLOGICAL).
Who is sponsoring clinical trial NCT03325075?
This trial is sponsored by ModernaTX, which has 90 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.